Highlights for Photocure's first quarter 2010:
(numbers for 2009 are adjusted for sale of Metvix/ Aktilite)

·       Hexvix revenues increased by 44% to NOK 14.0 million (9.7) in Q1 2010

·       Total revenue of NOK 18.1 million (9.7) in the quarter, including NOK
4.1 million in milestone revenue

·       Net result of NOK -13.9 million (-8.6) in Q1 2010

·       Cash holding of NOK 369.9 million per 31 March 2010

·       Dermatology:

·       Visonac: Inclusion completed in the last phase II study in January,
results from study expected in May 2010

·       Allumera: Second consumer trial starts in April 2010, results expected
in Q4 2010

·       Cancer:

·       Hexvix: Reimbursement approval in Germany, triggering milestone payment
of EUR 0.5 million from GE Healthcare

·       Cevira: Positive phase II results in April, efficacy and safety
demonstrated for the Cevira treatment

Please find the full financial report enclosed.

Photocure ASA's results for the first quarter 2010 will be presented at
Shippingklubben, Oslo, Norway, today at 5:00 pm CET by the President and CEO
Kjetil Hestdal and CFO Christian Fekete. The presentation will be transferred
live via webcast. The company will thereafter have its annual general meeting,
starting from 6:00 pm at the same location.

For more information, please contact:

Kjetil Hestdal, President and CEO
E-mail: kh@photocure.no
Mobile: +47 913 19535

Christian Fekete, CFO
E-mail: cf@photocure.no
Mobile: +47 916 42 938

www.photocure.com

About Photocure

Photocure is a Norwegian pharmaceutical company listed on the Oslo Stock
Exchange (OSE: PHO). The company develops and sells pharmaceuticals and medical
devices for the photodynamic treatment and diagnosis of cancer and selected
dermatology indications.

Photocure's commercial activities includes own marketing and sales in selected
markets as well as out-licensing on a regional or global basis prior to phase
III.

Photocure has one proprietary pharmaceutical product on the market: Hexvix®, for
the diagnosis of bladder cancer. Hexvix is approved in EU. In addition, the
company has developed a proprietary light source, which is used in combination
with the Visonac(TM) cream. Through worldwide studies, Photocure is continuously
testing its products for new indications, and the aim is to develop a pipeline
of follow-on products based on the Photocure Technology(TM) platform.

Photocure®, the Photocure logo and Hexvix® are registered trademarks of
Photocure ASA.

This information is subject of the disclosure requirements acc. to §5-12 vphl
(Norwegian Securities Trading Act)

[HUG#1409471]

Photocure ASA - 1st quarter 2010 results